European Evidence Based Consensus on the Diagnosis and Management of Crohn's Disease: Current Management

Overview

Journal Gut

Specialty Gastroenterology

Date 2006 Feb 17

PMID 16481629

Citations 151

Authors

S P L Travis

E F Stange

M Lemann

T Oresland

Y Chowers

A Forbes

G DHaens

G Kitis

A Cortot

C Prantera

P Marteau

J-F Colombel

P Gionchetti

Y Bouhnik

E Tiret

J Kroesen

M Starlinger

N J Mortensen

Affiliations

Soon will be listed here.

Abstract

This second section of the European Crohn's and Colitis Organisation (ECCO) Consensus on the management of Crohn's disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn's disease. The third section on special situations in Crohn's disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn's disease.

Citing Articles

Micro-fragmented adipose tissue-An innovative therapeutic approach: A narrative review.

Fu H, Wang C Medicine (Baltimore). 2025; 104(9):e41724.

PMID: 40020111 PMC: 11875617. DOI: 10.1097/MD.0000000000041724.

Depletion of core microbiome forms the shared background against diverging dysbiosis patterns in Crohn's disease and intestinal tuberculosis: insights from an integrated multi-cohort analysis.

Bajaj A, Markandey M, Samal A, Goswami S, Vuyyuru S, Mohta S Gut Pathog. 2024; 16(1):65.

PMID: 39511674 PMC: 11545864. DOI: 10.1186/s13099-024-00654-4.

Global, regional, and national burden of inflammatory bowel disease, 1990-2021: Insights from the global burden of disease 2021.

Lin D, Jin Y, Shao X, Xu Y, Ma G, Jiang Y Int J Colorectal Dis. 2024; 39(1):139.

PMID: 39243331 PMC: 11380638. DOI: 10.1007/s00384-024-04711-x.

Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.

Sipeki N, Kovats P, Deutschmann C, Schierack P, Roggenbuck D, Papp M World J Gastroenterol. 2023; 29(42):5728-5750.

PMID: 38075846 PMC: 10701337. DOI: 10.3748/wjg.v29.i42.5728.

Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.

Zhang N, Chan M, Li J, Brohawn P, Sun B, Vainshtein I CPT Pharmacometrics Syst Pharmacol. 2023; 12(12):1945-1959.

PMID: 37691451 PMC: 10725267. DOI: 10.1002/psp4.13044.

References

Nordgren S, Fasth S, Oresland T, Hulten L . Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol. 1994; 29(12):1122-8. DOI: 10.3109/00365529409094898. View

Heuman R, BOERYD B, Bolin T, Sjodahl R . The influence of disease at the margin of resection on the outcome of Crohn's disease. Br J Surg. 1983; 70(9):519-21. DOI: 10.1002/bjs.1800700904. View

Bernell O, Lapidus A, Hellers G . Recurrence after colectomy in Crohn's colitis. Dis Colon Rectum. 2001; 44(5):647-54; discussion 654. DOI: 10.1007/BF02234559. View

Green J, Lobo A, Giaffer M, Travis S, Watkins H . Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther. 2001; 15(9):1331-41. DOI: 10.1046/j.1365-2036.2001.01055.x. View

Farmer R, Whelan G, Fazio V . Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985; 88(6):1818-25. DOI: 10.1016/0016-5085(85)90006-x. View

Cantero Perona J, Pajares Garcia J . High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology. 1999; 46(28):2265-8. View

Tonelli F, Fedi M, Paroli G, Fazi M . Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. Dis Colon Rectum. 2004; 47(4):494-501. DOI: 10.1007/s10350-003-0084-8. View

van der Linden P, Sturkenboom M, Herings R, Leufkens H, Stricker B . Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002; 324(7349):1306-7. PMC: 113766. DOI: 10.1136/bmj.324.7349.1306. View

Sandborn W . Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997; 92(5):876-9. View

10.

Goodgame R, KIMBALL K, Akram S, Ike E, Ou C, SUTTON F . Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther. 2001; 15(12):1861-6. DOI: 10.1046/j.1365-2036.2001.01099.x. View

11.

Feagan B, McDonald J, Rochon J, Laupacis A, Fedorak R, Kinnear D . Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med. 1994; 330(26):1846-51. DOI: 10.1056/NEJM199406303302602. View

12.

Gendre J, Mary J, Florent C, Modigliani R, Colombel J, Soule J . Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology. 1993; 104(2):435-9. DOI: 10.1016/0016-5085(93)90411-5. View

13.

Colombel J, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas J . A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999; 94(3):674-8. DOI: 10.1111/j.1572-0241.1999.935_q.x. View

14.

Mylonakis E, Allan R, Keighley M . How does pouch construction for a final diagnosis of Crohn's disease compare with ileoproctostomy for established Crohn's proctocolitis?. Dis Colon Rectum. 2001; 44(8):1137-42; discussion 1142-3. DOI: 10.1007/BF02234634. View

15.

Connell W, Kamm M, Ritchie J, Lennard-Jones J . Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34(8):1081-5. PMC: 1374358. DOI: 10.1136/gut.34.8.1081. View

16.

Whittle S, Hughes R . Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004; 43(3):267-71. DOI: 10.1093/rheumatology/keh088. View

17.

Young-Fadok T, HallLong K, McConnell E, Gomez Rey G, Cabanela R . Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg Endosc. 2001; 15(5):450-4. DOI: 10.1007/s004640080078. View

18.

Modigliani R, Mary J, Simon J, Cortot A, Soule J, Gendre J . Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990; 98(4):811-8. DOI: 10.1016/0016-5085(90)90002-i. View

19.

Gross V, Andus T, Ecker K, Raedler A, Loeschke K, Plauth M . Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut. 1998; 42(4):493-6. PMC: 1727061. DOI: 10.1136/gut.42.4.493. View

20.

Te H, Schiano T, Kuan S, Hanauer S, Conjeevaram H, Baker A . Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000; 95(11):3150-6. DOI: 10.1111/j.1572-0241.2000.03287.x. View